biostudies-literatureUnknown111(12)Veulemans VUniversitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts<h4>Background</h4>Transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BAV) stenosis has become more frequent in the last years. This may pose challenges for long-time valve durability. Therefore, we aimed to evaluate the prevalence of bioprosthetic valve dysfunction (BVD) with the newest-generation devices in BAV stenosis up to one-year follow-up (FU).<h4>Methods</h4>The primary endpoint was defined as the prevalence of BVD during the first procedural year according to Valve Academic Research Consortium (VARC)-3 criteria. Secondary endpoints were defined as failure in device success and clinical endpoints according to VARC-3.<h4>Results</h4>A total of 107 patients were included. Of these, 34 subjects (31.8%) met the criteria for BVD during a mean FU of 263 ± 180 days,Clinical research in cardiology : official journal of the German Cardiac Society1358-1366https://www.ebi.ac.uk/biostudies/studies/S-EPMC9681687biostudies-literatureBioprosthetic valve dysfunction and failure after TAVI in bicuspid aortic valve stenosis during one-year follow-up according to VARC-3.PMC9681687Kelm MBinneboßel SHeermann JZeus Tde Backer ONuyens PMaier OVeulemans VJung CGoh SWestenfeld RfalseBioprosthetic valve dysfunction and failure after TAVI in bicuspid aortic valve stenosis during one-year follow-up according to VARC-3.<h4>Background</h4>Transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BAV) stenosis has become more frequent in the last years. This may pose challenges for long-time valve durability. Therefore, we aimed to evaluate the prevalence of bioprosthetic valve dysfunction (BVD) with the newest-generation devices in BAV stenosis up to one-year follow-up (FU).<h4>Methods</h4>The primary endpoint was defined as the prevalence of BVD during the first procedural year according to Valve Academic Research Consortium (VARC)-3 criteria. Secondary endpoints were defined as failure in device success and clinical endpoints according to VARC-3.<h4>Results</h4>A total of 107 patients were included. Of these, 34 subjects (31.8%) met the criteria for BVD during a mean FU of 263 ± 180 days,2022-01-01T00:00:00Z2022 Dec2025-04-04T22:35:37.122Z2025-04-04T22:35:37.122ZS-EPMC96816873576709810.1007/s00392-022-02052-9